1. Home
  2. TBPH vs RWAY Comparison

TBPH vs RWAY Comparison

Compare TBPH & RWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • RWAY
  • Stock Information
  • Founded
  • TBPH 2013
  • RWAY 2015
  • Country
  • TBPH United States
  • RWAY United States
  • Employees
  • TBPH N/A
  • RWAY N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • RWAY
  • Sector
  • TBPH Health Care
  • RWAY
  • Exchange
  • TBPH Nasdaq
  • RWAY Nasdaq
  • Market Cap
  • TBPH 485.8M
  • RWAY 390.5M
  • IPO Year
  • TBPH N/A
  • RWAY 2021
  • Fundamental
  • Price
  • TBPH $9.59
  • RWAY $10.55
  • Analyst Decision
  • TBPH Buy
  • RWAY Buy
  • Analyst Count
  • TBPH 4
  • RWAY 9
  • Target Price
  • TBPH $13.75
  • RWAY $11.82
  • AVG Volume (30 Days)
  • TBPH 217.1K
  • RWAY 500.4K
  • Earning Date
  • TBPH 11-12-2024
  • RWAY 11-12-2024
  • Dividend Yield
  • TBPH N/A
  • RWAY 3.79%
  • EPS Growth
  • TBPH N/A
  • RWAY N/A
  • EPS
  • TBPH N/A
  • RWAY 1.02
  • Revenue
  • TBPH $63,192,000.00
  • RWAY $150,078,000.00
  • Revenue This Year
  • TBPH $11.41
  • RWAY N/A
  • Revenue Next Year
  • TBPH $37.36
  • RWAY N/A
  • P/E Ratio
  • TBPH N/A
  • RWAY $10.29
  • Revenue Growth
  • TBPH 15.93
  • RWAY N/A
  • 52 Week Low
  • TBPH $7.44
  • RWAY $9.87
  • 52 Week High
  • TBPH $11.71
  • RWAY $13.74
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 50.13
  • RWAY 51.97
  • Support Level
  • TBPH $9.62
  • RWAY $10.14
  • Resistance Level
  • TBPH $10.08
  • RWAY $10.99
  • Average True Range (ATR)
  • TBPH 0.31
  • RWAY 0.24
  • MACD
  • TBPH -0.06
  • RWAY -0.03
  • Stochastic Oscillator
  • TBPH 25.00
  • RWAY 48.24

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About RWAY Runway Growth Finance Corp.

Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and Canada, with the majority of its portfolio invested in the United States.

Share on Social Networks: